Pfizer Inc. (NYSE:PFE) Shares Sold by Paladin Advisory Group LLC

Paladin Advisory Group LLC lessened its stake in Pfizer Inc. (NYSE:PFE) by 58.0% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 1,856 shares of the biopharmaceutical company’s stock after selling 2,558 shares during the period. Paladin Advisory Group LLC’s holdings in Pfizer were worth $47,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Lipe & Dalton increased its holdings in Pfizer by 17.7% in the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 400 shares during the last quarter. Beam Wealth Advisors Inc. boosted its position in Pfizer by 1.5% in the 4th quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company’s stock valued at $728,000 after buying an additional 401 shares during the period. Providence Capital Advisors LLC boosted its position in Pfizer by 0.4% in the 4th quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock valued at $3,034,000 after buying an additional 409 shares during the period. Donaldson Capital Management LLC boosted its position in Pfizer by 1.2% in the 4th quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock valued at $947,000 after buying an additional 410 shares during the period. Finally, Noesis Capital Mangement Corp boosted its position in Pfizer by 2.6% in the 4th quarter. Noesis Capital Mangement Corp now owns 16,357 shares of the biopharmaceutical company’s stock valued at $434,000 after buying an additional 413 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 0.6%

NYSE PFE opened at $24.46 on Thursday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market cap of $139.04 billion, a PE ratio of 17.34, a P/E/G ratio of 0.64 and a beta of 0.57. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The firm’s fifty day moving average is $22.96 and its two-hundred day moving average is $24.98.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period in the previous year, the business posted $0.82 earnings per share. Pfizer’s quarterly revenue was down 7.8% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.03%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio is presently 124.64%.

Analyst Upgrades and Downgrades

Several brokerages have commented on PFE. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group raised their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective for the company. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.